These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31245461)

  • 21. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
    Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [An overview of "the guideline for clinical research using human stem cells"].
    Matsuyama A
    Nihon Rinsho; 2008 May; 66(5):843-9. PubMed ID: 18464500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of guidance for the approval process of brand-new medical products and regenerative medicine products].
    Niimi S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2015; (133):1-7. PubMed ID: 26821464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japanese regulation of biosimilar products: past experience and current challenges.
    Arato T
    Br J Clin Pharmacol; 2016 Jul; 82(1):30-40. PubMed ID: 26987746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Research and Development Strategy for Future Embryonic Stem Cell-Based Therapy in Japan.
    Umezawa A; Sato Y; Kusakawa S; Amagase R; Akutsu H; Nakamura K; Kasahara M; Matsubara Y; Igarashi T
    JMA J; 2020 Oct; 3(4):287-294. PubMed ID: 33225099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment.
    Iwanaka T; Yamaza T; Sonoda S; Yoshimaru K; Matsuura T; Yamaza H; Ohga S; Oda Y; Taguchi T
    Stem Cell Res Ther; 2020 Mar; 11(1):134. PubMed ID: 32213198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian statistics and clinical trial designs for human cells and tissue products for regulatory approval.
    Jokura Y; Yano K; Watanabe N; Yamato M
    Regen Ther; 2016 Dec; 5():86-95. PubMed ID: 31245506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products.
    Lowdell MW; Thomas A
    Br J Haematol; 2017 Jan; 176(1):9-15. PubMed ID: 27748517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective.
    Maruyama Y; Noda S; Okudaira S; Sakurai A; Okura N; Honda F
    Adv Exp Med Biol; 2023; 1430():155-179. PubMed ID: 37526847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and Sustainable Substrates for Regenerative Medicine and Biotechnology.
    Laurent A; Hirt-Burri N; Scaletta C; Michetti M; de Buys Roessingh AS; Raffoul W; Applegate LA
    Front Bioeng Biotechnol; 2020; 8():557758. PubMed ID: 33195124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Development of CAR-T cell therapy using allogeneic iPS cells].
    Kaneko S
    Rinsho Ketsueki; 2022; 63(10):1454-1460. PubMed ID: 36351655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 3: Pig islet product manufacturing and release testing.
    Korbutt GS
    Xenotransplantation; 2009; 16(4):223-8. PubMed ID: 19799762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limbal stem cell transplantation: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2008; 8(7):1-58. PubMed ID: 23074512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of a keratinocyte and fibroblast bank for clinical applications in Japan.
    Nakano T; Katayama Y; Sakamoto M; Shimizu Y; Inoie M; Shimizu N; Yamanaka H; Tsuge I; Saito S; Morimoto N
    J Artif Organs; 2023 Mar; 26(1):45-52. PubMed ID: 35511369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights into the clinical development of regenerative medical products through a comparison of three cell-based products recently approved for limbal stem cell deficiency.
    Aketa N; Kasai M; Noda S; Asano J; Kunieda A; Kawanishi S; Maruyama Y; Honda F
    Ocul Surf; 2023 Jul; 29():220-225. PubMed ID: 37257692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constraining the Pluripotent Fate of Human Embryonic Stem Cells for Tissue Engineering and Cell Therapy - The Turning Point of Cell-Based Regenerative Medicine.
    Parsons XH
    Br Biotechnol J; 2013 Oct; 3(4):424-457. PubMed ID: 24926434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Report of the International Stem Cell Banking Initiative Workshop Activity: Current Hurdles and Progress in Seed-Stock Banking of Human Pluripotent Stem Cells.
    Kim JH; Kurtz A; Yuan BZ; Zeng F; Lomax G; Loring JF; Crook J; Ju JH; Clarke L; Inamdar MS; Pera M; Firpo MT; Sheldon M; Rahman N; O'Shea O; Pranke P; Zhou Q; Isasi R; Rungsiwiwut R; Kawamata S; Oh S; Ludwig T; Masui T; Novak TJ; Takahashi T; Fujibuchi W; Koo SK; Stacey GN
    Stem Cells Transl Med; 2017 Nov; 6(11):1956-1962. PubMed ID: 29067781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.